XML 68 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisition of EGEN Assets (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2016
Jun. 20, 2014
Jun. 20, 2014
Sep. 30, 2019
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Asset impairment charges, total                 $ 2,400,000      
Business combination, consideration transferred, liabilities incurred                     $ 4,500,000 $ 2,500,000
Finite-lived intangible assets, net           $ 397,805     397,805   568,292  
2018 Aspire Purchase Agreements [Member]                        
Finite-lived intangible assets, net           397,805     397,805      
Finite-lived intangible assets, accumulated amortization           1,193,409     1,193,409      
Aspire Purchase Agreement [Member]                        
Finite-lived intangible assets, net                     568,292  
Finite-lived intangible assets, accumulated amortization                     $ 1,022,922  
IPR&D Drug Technology Platforms [Member]                        
Asset impairment charges, total     $ 1,400,000                  
EGEN Inc [Member]                        
Potential future earn-out payments       $ 30,400,000 $ 30,400,000              
Payments to acquire businesses, gross         $ 3,000,000              
Stock issued during period, shares, acquisitions         241,590              
Business combination, consideration transferred, liabilities incurred       13,900,000       $ 13,100,000   $ 9,000,000   $ 12,500,000
Goodwill, acquisition                 2,000,000      
EGEN Inc [Member] | Purchase Agreement [Member]                        
Finite-lived intangible assets acquired                 $ 1,600,000      
Finite-lived intangible asset, useful life                 7 years      
Amortization expense           $ 56,829 $ 56,829   $ 170,487 $ 170,487    
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]                        
Asset impairment charges, total $ 9,400,000 $ 9,400,000                    
EGEN Inc [Member] | IPR&D Drug Technology Platforms [Member]                        
Indefinite lived intangible assets                 $ 24,200,000      
EGEN Inc [Member] | Maximum [Member]                        
Total purchase price for asset acquisition         $ 44,400,000              
Potential future earn-out payments       $ 30,400,000 $ 30,400,000